Physician profile
Basem R Farag
NPI 1457441974
$1,933.30
in general payments reported to CMS, 2019-2025
21 companies · $44.93 in 2025
The $44.93 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $12.61 · 2021: $364 · 2022: $671 · 2023: $354 · 2024: $313 · 2025: $44.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $396.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $315.32 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $172.07 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $151.01 | 2021-2023 | Steglatro, Belsomra, Verquvo |
| Glaxosmithkline, LLC. | $111.70 | 2021-2025 | Arexvy, Shingrix |
| Amgen INC. | $103.77 | 2019-2024 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $91.51 | 2022 | |
| Exact Sciences Corporation | $84.69 | 2023-2024 | Cologuard Collection Kit |
| Mannkind Corporation | $63.96 | 2021-2022 | |
| Amarin Pharma, INC. | $59.42 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $56.67 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $49.06 | 2023-2024 | Breztri |
| Biohaven Pharmaceuticals, INC. | $48.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $42.41 | 2022-2023 | |
| Boston Scientific Corporation | $41.85 | 2019-2023 | Wavewriter Alpha Prime 16 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $39.78 | 2019 | |
| Abbott Laboratories | $26.97 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.68 | 2024 | |
| Ucb, INC. | $21.69 | 2019 | |
| Corcept Therapeutics | $18.57 | 2024 | Korlym |
| Sobi, INC | $14.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basem Farag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.